Sofinnova Partners
在场
Sofinnova Partners 在 2 个国家有直接业务。
高管
查看带有其 63 名主要高管的组织结构图
Sofinnova Partners 搜索最多的简介
- Antoine Papiernik, Managing Partner and Chairman of the Board
- Stéphanie Huiban, Head of Information Systems
- Armance Bordes, General Counsel
高管在Sofinnova Partners变化
- Agnes Pauquet已作为Head of Human Resources加入公司 (新闻发布的2024十月16号).
- Karl Naegler已作为Partner, Life Sciences加入公司 (新闻发布的2024九月13号).
- Anta Gkelou 曾任 Principal, Capital Strategy, 现升职为 Partner, Capital Strategy (新闻发布的2024四月24号).
创建提醒
跟踪 Sofinnova Partners 的高管变动
基金
Sofinnova Partners 拥有 1,524 家竞争者，其中包括 BlackRock (美国(美洲))、Vanguard (美国(美洲)) 和 Blackstone Group (美国(美洲))。
Popular M&A news in 基金
- RIV Capital and Cansortium have announced they will merge (公布2024十月14号)..
- Janus Henderson Group 已收购 Victory Park Capital (公布2024十月7号).
- General Atlantic 已收购 Actis (公布2024十月3号).
基金 行业的其他推荐联系人
消息
Sofinnova Partners 的最新新闻稿
- BrightHeart Secures FDA Clearance for First AI Software Revolutionizing Prenatal Fetal Heart Ultrasound Evaluations — Sofinnova Partners
- Cure51 Launches NHS-Approved Study With Cambridge University Hospitals and Seven Other Leading UK Oncology Institutions to Unlock Cancer Survival Secrets — Sofinnova Partners
- Women's Health Company Freya Biosciences Announces Key $10.4 Million Strategic Investment — Sofinnova Partners
- Elicit Plant announces €45 Million Investment Round to Accelerate Global Expansion — Sofinnova Partners
- TechBio startup Cure51 selects 10x Genomics Visium HD for new drug discovery initiative — Sofinnova Partners
- AAVantgarde Founder and CSO is elected as President of the European Society of Gene and Cell Therapy (ESGCT) — Sofinnova Partners
- Gradient Denervation Technologies appoints Stanton Rowe to Board of Directors and receives FDA approval to expand early feasibility study — Sofinnova Partners
- Enhanced data security and quality via ISO 27001:2022 and SOC 2 certifications enables Moon Surgical to deliver actionable insights to healthcare providers — Sofinnova Partners
- Noema Pharma announces first patients dosed in Phase 2b study with Gemlapodect (NOE-105), a first-in-class investigational therapy for Tourette Syndrome — Sofinnova Partners
- Biotalys appoints Kamal El Mernissi as Chief Business Development Officer — Sofinnova Partners
- View more press releases Close
通过电子邮件
